Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
KEYNOTE-045: Pembrolizumab Maintains Overall Survival Benefit in Urothelial Cancer
29 března, 2021 10:33 pmJune 5, 2017 The PD-L1 inhibitor pembrolizumab continued to demonstrate an overall survival (OS) benefit compared with chemotherapy among...
Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis
29 března, 2021 10:30 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4572 Citation: J Clin Oncol 35,...
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)
29 března, 2021 10:26 pmMeeting: 2017 ASCO Annual Meeting Track: Genitourinary (Nonprostate) Cancer Abstract number: 4507 Citation: J Clin Oncol 35,...
Genomics May Provide New Insight Into Bladder Cancer Treatments
29 března, 2021 10:13 pmJune 4, 2017 In patients with upper tract urothelial carcinoma (UC) or who have early onset bladder cancer, screening...
GENITOURINÁRNÍ SEKCE ASCO 2017
29 března, 2021 10:07 pmJako každoročně se konala v Chicagu počátkem června konference Americké onkologické společnosti. Spočítat množství přednášek, posterů a abstraktů nebylo, stejně jako...
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study
29 března, 2021 10:03 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4014 Citation: J Clin Oncol 35,...
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer
29 března, 2021 9:57 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4003 Citation: J Clin Oncol 35,...
Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)
29 března, 2021 9:47 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3503 Citation: J Clin Oncol 35,...
Risk-Based Approach to Chemotherapy Duration Recommended for Stage III Colon Cancer
29 března, 2021 9:42 pmJune 4, 2017 In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly...
ONCOLOGICAL BENEFIT OF PARENCHYMA-PRESERVING HEPATECTOMY FOR COLORECTAL LIVER METASTASIS
29 března, 2021 9:39 pmMeeting: 2016 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3526 Citation: J Clin Oncol 34,...